DoD Lung Cancer Clinical Exploration Award

The summary for the DoD Lung Cancer Clinical Exploration Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

DoD Lung Cancer Clinical Exploration Award: The LCRP Clinical Exploration Award mechanism is being offered for the first time in FY13. The intent of the LCRP Clinical Exploration Award (CEA) is to support early-phase, proof-of-principle clinical trials and correlative studies to investigate hypothesis-based, innovative interventions and/or avenues of research that have the potential to resolve current clinical barriers and result in a profound impact on the clinical management of lung cancer. While therapeutic approaches proposed for testing through the CEA must represent novel, hypothesisbased, "outside-the-box" approaches for treating lung cancer, they may include therapies already in clinical use, or undergoing clinical testing, for other diseases, provided that the proposed use for lung cancer would lead to a major advancement for treating the disease. It is anticipated that outcomes from studies funded by this award will provide scientific rationale for subsequent development of larger, efficacy-based clinical trials of interventions that will transform lung cancer clinical care. Submissions from and partnerships with investigators at Military Medical Treatment Facilities, Military labs, and the Department of Veterans Affairs (VA) Medical Centers and research laboratories are encouraged. Clinical Trials: The CEA will support clinical trials encompassing Phase 0, Phase I, or pilot Phase II for drug or drug combinations, Class II or III devices, or other types of trials that conduct early clinical testing of innovative approaches for lung cancer.